Effect of Bifidobacterium animalis ssp. lactis GCL2505 on visceral fat accumulation in healthy Japanese adults: A randomized controlled trial

Bioscience of Microbiota, Food and Health

Volumn 35, Issue 4, 2016, Pages 163-171

  Takahashi, Shota ^a   Anzawa, Daisuke ^a   Takami, Kazuyo ^a   Ishizuka, Akihiro ^a   Mawatari, Takashi ^a   Kamikado, Kohei ^a   Sugimura, Haruhi ^b   Nishijima, Tomohiko ^a  

^a EZAKI GLICO CO LTD   (Japan)

^b Medical Corporation Shinkokai C'est lavie Shimbashi Clinic   (Japan)

Author keywords

Bifidobacterium; Overweight; Probiotics; Randomized trial; Visceral fat

Indexed keywords

EID: 84979063607     PISSN: 21866953     EISSN: 21863342     Source Type: Journal    
DOI: 10.12938/bmfh.2016-002     Document Type: Article

References (35)

1. Nikolopoulou A, Kadoglou NP. 2012. Obesity and metabolic syndrome as related to cardiovascular disease. Expert Rev Cardiovasc Ther 10: 933-939
2. Oka R, Kobayashi J, Yagi K, Tanii H, Miyamoto S, Asano A, Hagishita T, Mori M, Moriuchi T, Kobayashi M, Katsuda S, Kawashiri MA, Nohara A, Takeda Y, Mabuchi H, Yamagishi M. 2008. Reassessment of the cutoff values of waist circumference and visceral fat area for identifying Japanese subjects at risk for the metabolic syndrome. Diabetes Res Clin Pract 79: 474-481
3. Wajchenberg BL. 2000. Subcutaneous and visceral adipose tissue: their relation to the metabolic syndrome. Endocr Rev 21: 697-738
4. Alberti KG, Zimmet P, Shaw J. 2006. Metabolic syndrome-a new world-wide definition. A Consensus Statement from the International Diabetes Federation. Diabet Med 23: 469-480
5. Montague CT, O'Rahilly S. 2000. The perils of portliness: causes and consequences of visceral adiposity. Diabetes 49: 883-888
6. Fox CS, Massaro JM, Hoffmann U, Pou KM, Maurovich-Horvat P, Liu CY, Vasan RS, Murabito JM, Meigs JB, Cupples LA, D'Agostino RB Sr, O'Donnell CJ. 2007. Abdominal visceral and subcutaneous adipose tissue compartments: association with metabolic risk factors in the Framingham Heart Study. Circulation 116: 39-48
7. Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuño MI, Queipo-Ortuño M. 2014. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol 5: 190
8. Musso G, Gambino R, Cassader M. 2010. Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders. Curr Opin Lipidol 21: 76-83
9. Sekirov I, Russell SL, Antunes LC, Finlay BB. 2010. Gut microbiota in health and disease. Physiol Rev 90: 859-904
10. Musso G, Gambino R, Cassader M. 2010. Obesity, diabetes, and gut microbiota: the hygiene hypothesis expanded? Diabetes Care 33: 2277-2284
11. Angelakis E, Armougom F, Million M, Raoult D. 2012. The relationship between gut microbiota and weight gain in humans. Future Microbiol 7: 91-109
12. John K, Daniel N, Ruchi M. 2012. Impact of the gut microbiota on the development of obesity: current concepts. Am J Gastroenterol Suppl 1: 22-27
13. Schwiertz A, Taras D, Schäfer K, Beijer S, Bos NA, Donus C, Hardt PD. 2010. Microbiota and SCFA in lean and overweight healthy subjects. Obesity (Silver Spring) 18: 190-195
14. Delzenne NM, Neyrinck AM, Bäckhed F, Cani PD. 2011 Targeting gut microbiota in obesity: effects of prebiotics and probiotics. Nat Rev Endocrinol 7: 639-646
15. Festi D, Schiumerini R, Eusebi LH, Marasco G, Taddia M, Colecchia A. 2014. Gut microbiota and metabolic syndrome. World J Gastroenterol 20: 16079-16094
16. Chiu YH, Lin SL, Tsai JJ, Lin MY. 2014. Probiotic actions on diseases: implications for therapeutic treatments. Food Funct 5: 625-634
17. Ruan Y, Sun J, He J, Chen F, Chen R, Chen H. 2015. Effect of probiotics on glycemic control: a systematic review and meta-analysis of randomized, controlled trials. PLoS One 10: e0132121
18. Park S, Bae JH. 2015. Probiotics for weight loss: a systematic review and meta-analysis. Nutr Res 35: 566-575
19. Gill HS, Rutherfurd KJ, Prasad J, Gopal PK. 2000. Enhancement of natural and acquired immunity by Lactobacillus rhamnosus (HN001), Lactobacillus acidophilus (HN017) and Bifidobacterium lactis (HN019). Br J Nutr 83: 167-176
20. Taipale T, Pienihäkkinen K, Isolauri E, Larsen C, Brockmann E, Alanen P, Jokela J, Söderling E. 2011. Bifidobacterium animalis subsp. lactis BB-12 in reducing the risk of infections in infancy. Br J Nutr 105: 409-416
21. Ishizuka A, Tomizuka K, Aoki R, Nishijima T, Saito Y, Inoue R, Ushida K, Mawatari T, Ikeda T. 2012. Effects of administration of Bifidobacterium animalis subsp. lactis GCL2505 on defecation frequency and bifidobacterial microbiota composition in humans. J Biosci Bioeng 113: 587-591
22. Tanaka Y, Takami K, Nishijima T, Aoki R, Mawatari T, Ikeda T. 2015. Short-and long-term dynamics in the intestinal microbiota following ingestion of Bifidobacterium animalis subsp. lactis GCL2505. Biosci Microbiota Food Health 34: 77-85
23. Schulz KF, Altman DG, Moher D, CONSORT Group 2011 CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Int J Surg 9: 672-677
24. Barba C, Cavalli-Sforza T, Cutter J, Darnton-Hill I, Deurenberg P, Deurenberg-Yap M, Gill T, WHO Expert Consultation 2004. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 363: 157-163
25. Ryo M, Kishida K, Nakamura T, Yoshizumi T, Funahashi T, Shimomura I. 2014. Clinical significance of visceral adiposity assessed by computed tomography: a Japanese perspective. World J Radiol 6: 409-416
26. Chaston TB, Dixon JB. 2008. Factors associated with percent change in visceral versus subcutaneous abdominal fat during weight loss: findings from a systematic review. Int J Obes 32: 619-628
27. Farb MG, Gokce N, Reynolds JV. 2015. Visceral adiposopathy: a vascular perspective. Horm Mol Biol Clin Investig 21: 125-136
28. Kadowaki T, Sekikawa A, Murata K, Maegawa H, Takamiya T, Okamura T, El-Saed A, Miyamatsu N, Edmundowicz D, Kita Y, Sutton-Tyrrell K, Kuller LH, Ueshima H. 2006. Japanese men have larger areas of visceral adipose tissue than Caucasian men in the same levels of waist circumference in a population-based study. Int J Obes 30: 1163-1165
29. Matsuzawa Y. 2005. Metabolic syndrome-definition and diagnostic criteria in Japan. J Atheroscler Thromb 12: 301
30. Stenman LK, Waget A, Garret C, Klopp P, Burcelin R, Lahtinen S. 2014. Potential probiotic Bifidobacterium animalis ssp. lactis 420 prevents weight gain and glucose intolerance in diet-induced obese mice. Benef Microbes 5: 437-445
31. Chen J, Wang R, Li XF, Wang RL. 2012. Bifidobacterium adolescentis supplementation ameliorates visceral fat accumulation and insulin sensitivity in an experimental model of the metabolic syndrome. Br J Nutr 107: 1429-1434
32. Kondo S, Xiao JZ, Satoh T, Odamaki T, Takahashi S, Sugahara H, Yaeshima T, Iwatsuki K, Kamei A, Abe K. 2010. Antiobesity effects of Bifidobacterium breve strain B-3 supplementation in a mouse model with highfat diet-induced obesity. Biosci Biotechnol Biochem 74: 1656-1661
33. Minami J, Kondo S, Yanagisawa N, Odamaki T, Xiao JZ, Abe F, Nakajima S, Hamamoto Y, Saitoh S, Shimoda T. 2015. Oral administration of Bifidobacterium breve B-3 modifies metabolic functions in adults with obese tendencies in a randomised controlled trial. J Nutr Sci 4: e17
34. Aoki R, Tsuchida S, Arai Y, Ohno K, Nishijima T, Mawatari T, Mikami Y, Ushida K. 2016. Effect of Bifidobacterium animalis subsp. lactis GCL2505 on the physiological function of intestine in a rat model. Food Sci Nutr
35. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. 2007. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia 50: 2374-2383